Stealthy NeuroVasc Technologies said yesterday that it raised a $1 million funding round, taking it’s total raise since last year to nearly $2.5 million.
Laguna Hills, Calif.-based NeuroVasc is led by CEO Ev3 veteran Jianlu Ma, according to regulatory filings. According to the LinkedIn page of chairman Jeff Peters, the former Anulex Technologies CEO who’s also an Ev3 alum, NeuroVascular Technologies is developing an interventional neuroradiology technology to treat ischemic stroke.
The $1 million round included 3 unnamed investors, according to 1 of the filings. NeuroVascular Technologies reported raising $1.45 million in November 2015, from 4 unnamed investors.
Blockade Medical CEO David Ferrera, who was listed as a board member in the Nov. 18, 2015, filing, is not listed as a director in the most recent filing. That may be because of the acquisition earlier this year of Blockade by European medtech firm Balt International for an undisclosed amount.